CN114766619A - Health-care product oral liquid for delaying senility and preparation method thereof - Google Patents
Health-care product oral liquid for delaying senility and preparation method thereof Download PDFInfo
- Publication number
- CN114766619A CN114766619A CN202210597666.4A CN202210597666A CN114766619A CN 114766619 A CN114766619 A CN 114766619A CN 202210597666 A CN202210597666 A CN 202210597666A CN 114766619 A CN114766619 A CN 114766619A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- polysaccharide
- polypeptide
- health
- sheep placenta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 210000002826 placenta Anatomy 0.000 claims abstract description 66
- 150000004676 glycans Chemical class 0.000 claims abstract description 63
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 63
- 239000005017 polysaccharide Substances 0.000 claims abstract description 63
- 241001494479 Pecora Species 0.000 claims abstract description 61
- 229920001184 polypeptide Polymers 0.000 claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 61
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 45
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 45
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 42
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 42
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 40
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 40
- 230000036541 health Effects 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 33
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 claims abstract description 16
- 229940089837 amygdalin Drugs 0.000 claims abstract description 16
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 claims abstract description 16
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 7
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 45
- 230000007062 hydrolysis Effects 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 28
- 239000004365 Protease Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000413 hydrolysate Substances 0.000 claims description 25
- 241000628997 Flos Species 0.000 claims description 24
- 210000000582 semen Anatomy 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 244000241838 Lycium barbarum Species 0.000 claims description 22
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 22
- 229940088598 enzyme Drugs 0.000 claims description 22
- 108090000526 Papain Proteins 0.000 claims description 20
- 229940055729 papain Drugs 0.000 claims description 20
- 235000019834 papain Nutrition 0.000 claims description 20
- 235000013399 edible fruits Nutrition 0.000 claims description 19
- 235000015468 Lycium chinense Nutrition 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 claims description 14
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 13
- 108091005658 Basic proteases Proteins 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 230000009758 senescence Effects 0.000 claims description 8
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 7
- 102000000344 Sirtuin 1 Human genes 0.000 abstract description 2
- 108010041191 Sirtuin 1 Proteins 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000011194 food seasoning agent Nutrition 0.000 abstract 1
- 229930195259 hydroxysafflor yellow Natural products 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 238000002137 ultrasound extraction Methods 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- 238000004537 pulping Methods 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- 241000283898 Ovis Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 244000228451 Stevia rebaudiana Species 0.000 description 4
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 4
- 230000003005 anti-senility effect Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 239000009724 Salvia extract Substances 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 102000000477 Sirtuin 2 Human genes 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical group OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 lauric acid modified superoxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a health care product oral liquid for delaying senility and a preparation method thereof. The invention adopts the coproduction preparation technology of polypeptide polysaccharide for the first time, takes sheep placenta freeze-dried powder, medlar, safflower, longan pulp and peach kernel as raw materials to prepare mixed liquid rich in polypeptide (sheep placenta polypeptide) and polysaccharide (medlar polysaccharide and longan polysaccharide), and can be prepared into the health-care oral liquid for delaying senility after seasoning. The health product oral liquid for delaying senility contains polypeptide 700-1900mg/100mL, polysaccharide 200-2000mg/100mL, hydroxysafflor yellow A6-10mg/100mL and amygdalin 24-40mg/100mL, and the preparation can obviously improve the SIRT1 protein reduction caused by senility, thereby playing the role of delaying senility.
Description
Technical Field
The invention relates to a health care product oral liquid for delaying senility and a preparation method thereof.
Background
The sheep placenta freeze-dried powder is prepared by taking sheep placenta as a raw material, the nutritional structure and the composition of the sheep placenta are most similar to those of human placenta, and the sheep placenta contains abundant proteins, but has high molecular weight and is not beneficial to absorption and utilization by a human body. The polypeptide molecules need to be obtained by a degradation technology, have small molecular weight, are easy to absorb, and have the physiological functions of improving the immunity of the organism, improving the digestion function of the organism, resisting oxidation, resisting fatigue, delaying senility and the like.
Arillus longan is aril of arillus longan of Sapindaceae. Harvesting mature fruits in summer and autumn, drying, removing shells and cores, and drying in the sun until the fruits are dry and sticky. The functions and indications recorded in the pharmacopoeia are tonifying heart and spleen, nourishing blood and tranquilization. Can be used for treating deficiency of both qi and blood, palpitation, amnesia, insomnia, blood deficiency, and sallow complexion. The exterior and interior of the product are protected as longan: anti-aging action of longan pulp is reported in Life-prolonging anti-aging (Bao Guo, longan life-prolonging anti-aging [ J ], medicine and health care, 1996, 03).
The fructus Lycii is dry mature fruit of Solanaceae plant fructus Lycii, has sweet taste and neutral nature, and has effects of nourishing liver and kidney, replenishing vital essence and improving eyesight. Studies of Dashou Zhi et al reported anti-aging activities of Lycium barbarum and Lycium barbarum polysaccharides (Dashou Zhi et al. Studies of Lycium barbarum and Lycium barbarum polysaccharides for anti-aging and prolonging life [ J ], Ningxia medical college, 1992, 01).
The Carthami flos is dried flower of Carthamus Tinctorius of Compositae. Picking the flower when the flower turns yellow red in summer, and drying in the shade or in the sun. The functions and indications recorded in the pharmacopoeia are blood circulation and meridian obstruction, stasis dissipation and pain relief. Can be used for treating amenorrhea, dysmenorrhea, lochiorrhea, abdominal mass, thoracic obstruction, cardialgia, abdominal pain due to blood stasis, pricking pain in chest and hypochondrium, traumatic injury, and swelling and pain due to pyocutaneous disease. Zhang Mingcui et al, professor of Hebei medical university, reported the anti-aging action and mechanism of safflower (Zhang Mingcui, et al, experimental study of anti-aging action of safflower [ J ]. Chinese herbal medicine, 2001, 01).
The semen Persicae is dry mature seed of Prunus persica or Prunus davidiana of Rosaceae. Harvesting after the fruits are ripe, removing pulp and nucleocapsid, taking out seeds, and drying in the sun. The functions and indications recorded in the pharmacopoeia are activating blood circulation to dissipate blood stasis, relaxing bowel, relieving cough and asthma. Can be used for treating amenorrhea, dysmenorrhea, abdominal mass, pulmonary abscess, acute appendicitis, traumatic injury, intestinal dryness, constipation, cough, and asthma. The research of Zhaobei Cabernet study by Yangbean university reports the influence of the peach kernel ethanol extract on the anti-aging effect of subacute aged rats.
SIRT1 (Sirtuin 2 related enzyme 1) is a NAD + -dependent deacetylase and is involved in physiological activities such as cell proliferation, metabolism and apoptosis. Literature research reports that the SIRT1 signal path is activated, the SIRT1 protein amount is increased, the biological life can be prolonged, the NF-kB signal path can be directly regulated to participate in regulation and control of the aging process, and the aging can be delayed by regulating and controlling the mitochondrial function and reducing oxidative stress damage, so that the method has a certain relation with the free radical theory and the inflammatory theory involved in the modern aging theory. (Tang BL.Sirt1 and the mitochondria [ J ] Mol Cells,2016,39: 87-95.).
Although the sheep placenta lyophilized powder, the longan pulp, the wolfberry fruit, the safflower and the peach seed are reported to be related to the anti-aging effect, the anti-aging preparation containing the sheep placenta lyophilized powder, the longan pulp, the wolfberry fruit, the safflower and the peach seed at present cannot fully exert the functions of the raw materials, and the targeted anti-aging effect is achieved, for example, the SIRT1 protein reduction caused by aging is improved.
Disclosure of Invention
The invention aims to provide an anti-aging health-care product oral liquid, which comprises 700-1900mg/100mL of polypeptide, 200-2000mg/100mL of polysaccharide, 6-10mg/100mL of hydroxysafflor yellow A and 24-40mg/100mL of amygdalin in terms of the total volume of the anti-aging health-care product oral liquid.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide.
The polysaccharide includes sheep placenta polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
The invention also aims to provide a preparation method of the health-care product oral liquid for delaying senility, which comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
pulverizing Carthami flos and semen Persicae, adding solvent, ultrasonic extracting, and filtering the extractive solution; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, adding water into the sheep placenta freeze-dried powder, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution, adding complex enzyme for hydrolysis, and performing hydrolysis reaction for 1-2 hours to obtain stage 1 hydrolysate. The hydrolyzed object at this stage is lyophilized powder of placenta caprae seu ovis.
And S2.2, adding the wolfberry fruits, the arillus longan, the safflower dregs and the peach kernels prepared in the step S1 into the stage 1 hydrolysate, adding papain, continuing hydrolysis, and carrying out hydrolysis reaction for 1-2 hours to obtain the stage 2 hydrolysate. The hydrolysis targets in the stage 1 are hydrolysate, fructus Lycii, arillus longan, Carthami flos and semen Persicae residue.
And S2.3, heating the hydrolysate in the stage 2 to inactivate the complex enzyme, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adjusting the water content in the solution to the required concentration to obtain the health-care oral liquid for delaying senility.
The health product oral liquid for delaying senescence is an oral medicament, and a proper amount of flavoring agent can be added in the blending process to improve the mouthfeel, wherein 1 or 2 of white granulated sugar, xylitol and stevia rebaudiana are preferably selected as the flavoring agent.
The dosage ratio of the sheep placenta lyophilized powder, safflower, peach kernel, medlar and longan aril is 1: (0.8-2.5): (1.8-6): (1.9-5.5): (1.9-5).
According to the mass percentage, the water content of the health care product oral liquid for delaying senility prepared in the step S3 is 80-95%.
The dosage of the complex enzyme in the step S2.1 is 1 to 3.5 percent of the weight of the sheep placenta freeze-dried powder.
The compound enzyme is compounded by papain and alkaline protease, wherein the papain: the ratio of alkaline protease used was 1: 1 to 3: 1.
in the step S2.2, the dosage of the papain is 1.8 to 3 percent of the weight of the medlar.
In the step S2.1, the cooling temperature of the sheep placenta freeze-dried powder water solution is controlled to be 35-45 ℃.
The hydrolysis reaction of step S2.1 is carried out at a pH of 8-9.
The hydrolysis reaction conditions of step S2.2 are carried out at a pH of 5-7.
The health care product oral liquid for delaying senility prepared by the preparation method comprises the polypeptide content of 700-1900mg/100mL, the polysaccharide content of 200-2000mg/100mL, the hydroxysafflor yellow A content of 6-10mg/100mL and the amygdalin content of 24-40mg/100mL based on the total volume.
The principle and the beneficial effects of the invention are as follows:
the health-care product oral liquid for delaying senility contains polypeptide (sheep placenta polypeptide, wolfberry fruit polypeptide and longan pulp polypeptide), polysaccharide (sheep placenta polysaccharide, wolfberry fruit polysaccharide and longan polysaccharide) and hydroxysafflor yellow A (C)27H32O16) Amygdalin (C)20H27NO11) (ii) a Wherein, the hydroxysafflor yellow A is the most effective water-soluble part of the pharmacological efficacy of the safflower; amygdalin is a water-soluble extract of peach kernel. Through the cooperation of the active ingredients, the reduction of SIRT1 protein caused by aging can be obviously improved, and the SIRT1 protein level is increased, thereby playing a role in delaying aging.
The preparation method disclosed by the invention has the advantages that the enzyme type screening and hydrolysis process are searched, the co-production preparation process of polypeptide and polysaccharide is realized, the sheep placenta lyophilized powder, the wolfberry fruit, the arillus longan, the safflower and the peach kernel are used as main raw materials, and the sheep placenta lyophilized powder polypeptide, the wolfberry fruit polysaccharide and the arillus longan polysaccharide are hydrolyzed to generate the sheep placenta polysaccharide, the wolfberry fruit polypeptide and the arillus longan polypeptide, so that different types of active ingredients are efficiently utilized, the content of active substances in the preparation is increased, and the functional value of the raw materials is more fully exerted; meanwhile, the preparation process is simplified, the production efficiency is improved, the energy consumption is reduced, and the cost is saved; the process has good stability and strong repeatability.
In order to ensure the stability and effectiveness of the preparation, the invention provides the content standards of 4 index components of polypeptide, polysaccharide, hydroxysafflor yellow A and amygdalin; the health-care product oral liquid for delaying senility obtained by the process can obviously improve the reduction of SIRT1 protein caused by senility and increase the SIRT1 protein level, thereby playing a role in delaying senility.
Drawings
FIG. 1 is a schematic diagram showing the effect of SIRT1 protein expression in aged cardiomyocytes of the oral liquid samples of the anti-aging health products of examples 1 to 7.
Detailed Description
The scheme of the present application is further described below with reference to specific examples:
example 1
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing and pulverizing 2.18kg of Carthami flos and 4.01kg of semen Persicae, sieving with 80 mesh sieve, adding 70% ethanol 40 times of the total weight of Carthami flos and semen Persicae, and performing ultrasonic extraction at 60 deg.C and 70kHz for 5 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 1.12kg of sheep placenta freeze-dried powder, adding 4L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 45 ℃, adjusting the pH value to 8, and then adding 18.3g of complex enzyme for hydrolysis, wherein the complex enzyme is prepared by compounding trypsin and papain: the ratio of alkaline protease used was 5: 3; hydrolysis reaction for 1 hour to obtain stage 1 hydrolysate.
And S2.2, pulping 4.99kg of barbary wolfberry fruit and 5.04kg of longan pulp, adding the pulped barbary wolfberry fruit and the dregs of the safflower and the peach kernel prepared in the step S1 into the stage 1 hydrolysate, adding 9L of water, adding 119g of papain, adjusting the pH value to 5, continuing to hydrolyze, and performing hydrolysis reaction for 1 hour to obtain the stage 2 hydrolysate.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 30 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 100L of the health-care product oral liquid for delaying senescence.
30g of stevia rebaudiana as a flavoring agent is added into the health-care oral liquid for delaying senility, so that a finished product of the anti-aging oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 712mg/100mL, the polysaccharide content of 509mg/100mL, the amygdalin content of 25mg/100mL and the hydroxysafflor yellow A content of 6.1mg/100mL based on the total volume.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes sheep placenta polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
Example 2
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing and crushing 0.298kg of safflower and 0.413kg of peach kernel, sieving with a 80-mesh sieve, adding 70% ethanol 35 times of the total weight of safflower and peach kernel, and performing ultrasonic extraction at the ultrasonic frequency of 70kHz and the temperature of 60 ℃ for 5 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 0.209kg of sheep placenta freeze-dried powder, adding 1L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 45 ℃, adjusting the pH value to 8, then adding 6.1g of complex enzyme for hydrolysis, wherein the complex enzyme is prepared by compounding trypsin and papain: the ratio of alkaline protease used was 1: 1; hydrolysis reaction for 1 hour to obtain stage 1 hydrolysate.
And S2.2, adding 0.408kg of wolfberry fruit and 0.412kg of longan pulp into the stage 1 hydrolysate together with the residues of the safflower and the peach kernel prepared in the step S1 after pulping, adding 1.5L of water, adding 9g of papain, adjusting the pH value to 5, continuing to hydrolyze, and carrying out hydrolysis reaction for 1 hour to obtain the stage 2 hydrolysate.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 25 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 10L of the health-care product oral liquid for delaying senescence.
3g of flavoring agent xylitol is added into the health care product oral liquid for delaying senility, and the finished product of the anti-senility oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 1510mg/100mL, the polysaccharide content of 419mg/100mL, the amygdalin content of 28mg/100mL and the hydroxysafflor yellow A content of 9.3mg/100mL based on the total volume.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes sheep placenta polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
Example 3
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing and pulverizing Carthami flos 0.339kg and semen Persicae 0.697kg, sieving with 80 mesh sieve, adding 70% ethanol 35 times of the total weight of Carthami flos and semen Persicae, and performing ultrasonic extraction at 60kHz and 60 deg.C for 5 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 0.255kg of sheep placenta freeze-dried powder, adding 1L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 45 ℃, adjusting the pH value to 7, then adding 6.8g of complex enzyme for hydrolysis, wherein the complex enzyme is prepared by compounding trypsin and papain: the ratio of alkaline protease used was 2: 1; hydrolysis reaction is carried out for 1 hour to obtain stage 1 hydrolysate.
And S2.2, adding 0.613kg of wolfberry fruit and 0.598kg of longan pulp into the stage 1 hydrolysis liquid together with the residues of the safflower and the peach kernel prepared in the step S1 after pulping, adding 2L of water, adding 12g of papain, adjusting the pH value to be 6, continuing to hydrolyze, and performing hydrolysis reaction for 1.5 hours to obtain the stage 2 hydrolysis liquid.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 35 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 10L of the health-care product oral liquid for delaying senescence.
3.4g of flavoring agent xylitol is added into the health care product oral liquid for delaying senility, and the finished product of the anti-senility oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 1880mg/100mL, the polysaccharide content of 731mg/100mL, the amygdalin content of 31mg/100mL and the hydroxysafflor yellow A content of 9.9mg/100mL based on the total volume.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes sheep placenta polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
Example 4
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing 3.32kg of safflower and 8.01kg of peach kernel, crushing, sieving with a 80-mesh sieve, adding 70% ethanol 45 times of the total weight of safflower and peach kernel, and performing ultrasonic extraction at 70kHz and 60 ℃ for 5 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 2.49kg of sheep placenta freeze-dried powder, adding 5L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 50 ℃, adjusting the pH value to 8, adding 36g of complex enzyme for hydrolysis, wherein the complex enzyme is prepared by compounding trypsin and papain: the ratio of alkaline protease used was 8: 3; hydrolysis reaction is carried out for 1.5 hours to obtain stage 1 hydrolysate.
And S2.2, adding beaten fructus lycii 9.93kg and arillus longan 10.01kg into the stage 1 hydrolysate together with the residues of the safflower and the peach kernel prepared in the step S1, adding 20L of water, adding 260g of papain, adjusting the pH value to be 6, continuing to hydrolyze, and performing hydrolysis reaction for 1.5 hours to obtain the stage 2 hydrolysate.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 30 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 100L of the health-care oral liquid for delaying senescence.
38g of stevia rebaudiana as a flavoring agent is added into the health-care oral liquid for delaying senility, so that a finished product of the anti-aging oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 1790mg/100mL, the polysaccharide content of 1380mg/100mL, the amygdalin content of 39mg/100mL and the hydroxysafflor yellow A content of 9.8mg/100mL based on the total volume of the oral liquid.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes placenta Caprae Seu Ovis polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
Example 5
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing and crushing 2.03kg of safflower and 7.55kg of peach kernel, sieving by a 80-mesh sieve, adding 70% ethanol which is 40 times of the total weight of the safflower and the peach kernel, and performing ultrasonic extraction at the ultrasonic frequency of 70kHz and the temperature of 60 ℃ for 5 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 2.51kg of sheep placenta freeze-dried powder, adding 4L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 45 ℃, adjusting the pH value to 8, then adding 30g of complex enzyme for hydrolysis, wherein the complex enzyme is prepared by compounding trypsin and papain: the ratio of alkaline protease used is 7: 3; hydrolysis reaction is carried out for 1.5 hours to obtain stage 1 hydrolysate.
And S2.2, adding 13.30kg of wolfberry fruit and 12.39kg of longan pulp into the stage 1 hydrolysis liquid together with the residues of the safflower and the peach kernel prepared in the step S1 after pulping, adding 25L of water, adding 450g of papain, adjusting the pH value to be 6, continuing to hydrolyze, and performing hydrolysis reaction for 1.5 hours to obtain the stage 2 hydrolysis liquid.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 25 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 100L of the health-care product oral liquid for delaying senescence.
41g of flavoring agent xylitol is added into the health care product oral liquid for delaying senility, and the finished product of the anti-senility oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 1810mg/100mL, the polysaccharide content of 1770mg/100mL, the amygdalin content of 34mg/100mL and the hydroxysafflor yellow A content of 6.0mg/100mL based on the total volume.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes placenta Caprae Seu Ovis polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
Example 6
A preparation method of a health care product oral liquid for delaying senility comprises the following steps:
s1, extracting flos Carthami and semen Persicae;
mixing and crushing 0.340kg of safflower and 0.798kg of peach kernel, sieving by a 80-mesh sieve, adding 70% ethanol 40 times of the total weight of the safflower and the peach kernel, and performing ultrasonic extraction at 60kHz and 60 ℃ for 6 min. Filtering the extracting solution after extraction; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain the residues of the safflower and the peach kernel.
S2, hydrolyzing the raw materials in stages;
s2.1, taking 0.137kg of sheep placenta freeze-dried powder, adding 1L of water, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution to 45 ℃, adjusting the pH value to 8, then adding 3.3g of complex enzyme for hydrolysis, wherein the complex enzyme is formed by compounding trypsin and papain: the ratio of alkaline protease used is 2: 1; hydrolysis reaction for 1.5 hours to obtain stage 1 hydrolysate.
And S2.2, adding 0.559kg of wolfberry fruit and 0.560kg of longan pulp into the stage 1 hydrolysate together with the residues of the safflower and the peach kernel prepared in the step S1 after pulping, adding 2L of water, adding 14g of papain, adjusting the pH value to 5, continuing to hydrolyze, and carrying out hydrolysis reaction for 1.5 hours to obtain the stage 2 hydrolysate.
And S2.3, heating and boiling the hydrolysate in the stage 2 for 25 minutes to inactivate the protease, and centrifuging to remove impurities to obtain a hydrolysis mixed solution.
S3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adding a proper amount of water to obtain 10L of the health-care oral liquid for delaying senescence.
2g of flavoring agent xylitol and 2g of stevia rebaudiana are added into the health care product oral liquid for delaying senility, so that a finished product of the anti-senility oral liquid can be obtained.
The health care product oral liquid for delaying senility prepared by the preparation method has the polypeptide content of 730mg/100mL, the polysaccharide content of 526mg/100mL, the amygdalin content of 38mg/100mL and the hydroxysafflor yellow A content of 9.9mg/100mL based on the total volume of the oral liquid.
The polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes placenta Caprae Seu Ovis polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
In the health oral liquid for delaying aging of examples 1 to 6, the method for measuring the content of the index components comprises the following steps:
the content of the polypeptide adopts trichloroacetic acid precipitation method;
the polysaccharide content is measured by a phenol-sulfuric acid method;
the amygdalin content determination method comprises determining by high performance liquid chromatography (general rule 0512), and testing chromatographic conditions and system applicability, with octadecylsilane chemically bonded silica as filler and methanol-water (20: 80) as mobile phase; the detection wavelength was 210 nm. The number of theoretical plates is not less than 3000 calculated according to amygdalin peak.
The method for measuring the content of hydroxysafflor yellow A comprises measuring by high performance liquid chromatography (general rule 0512), and performing chromatographic condition and system applicability test by using octadecylsilane chemically bonded silica as filler; methanol-acetonitrile-0.7% phosphoric acid solution (26: 2: 72) is used as a mobile phase; the detection wavelength was 403 nm. The number of theoretical plates is not less than 3000 calculated according to the peak of hydroxysafflor yellow A.
Example 7
The Chinese patent application (CN104770738A) discloses a sheep placenta lyophilized powder compound preparation, which comprises sheep placenta lyophilized powder, safflower extract, medlar extract, longan extract and other raw materials, and has the effect of delaying senility, namely the preparation for delaying senility.
This example was carried out using this protocol as prior art to prepare comparative samples. The preparation method comprises the following steps:
255g of sheep placenta freeze-dried powder, 14g of grape seed extract, 7g of salvia extract, 5.8g of cogongrass rhizome extract, 3.1g of chrysanthemum extract, 85mg of zinc gluconate, 2.9g of vitamin C, 430mg of vitamin E, 10g of beta-carotene, 14g of fish collagen protein powder, 5mg of lauric acid modified superoxide dismutase, 8.5g of tea polyphenol, 4g of safflower extract, 6.5g of rose extract, 8.5g of sea buckthorn extract, 70g of wolfberry extract, 300mg of longan extract, 10g of coix seed extract, 14g of dioscorea opposita rhizome extract and 8.5g of water-soluble pearl powder are weighed, a proper amount of sodium carboxymethyl starch is added into the raw materials, and after granulation, a proper amount of pure water is used for dissolving the oral liquid of 10L for standby.
The oral liquid of the health care product for delaying senility prepared in the examples 1 to 7 is tested for improving the reduction of the SIRT1 protein caused by senility.
Test method
Cell culture: h9c2 rat cardiomyocytes were cultured in DMEM medium (containing 10% fetal calf serum, penicillin 100U mL-1, streptomycin 100U mL-1). The flasks were placed in a 37 ℃, 5% CO2 sterile incubator, and when H9c2 rat cardiomyocytes grew to 80%, they were passaged by digestion with 0.25% trypsin, inoculated into 96-well plates, and incubated in the incubator for 24H.
Sample treatment: 100mL of the oral liquid of examples 1-7 was taken for use.
Protein immunoblotting to detect SRIT1 protein expression, H9c2 rat cardiac muscle cell suspension in 5X 105one/mL was inoculated in 96-well plates, 2mL per well, and 9 groups were set: 1. a normal control group; d-galactose group (50 mol. L-1); 3. example 1 sample; 4. example 2 sample; 5. example 3 sample; 6. example 4 sample; 7. example 5 sample; 8. example 6 sample; 9. example 7 sample. And arranging 6 multiple wells in each well, after 24 hours of action, collecting cells, cracking the cells, extracting total protein, detecting the concentration of each protein according to a BCA protein quantification method, and detecting by using a gel imaging system. Western blot images were analyzed using Image J software and data were analyzed using SPSS 16.0 software.
Second, experimental results
As shown in figure 1 of the specification, the closer the relative intensity of SIRT1 to the control group shows the stronger the effect on the expression level of SIRT1 protein.
And example 7 is an anti-aging preparation prepared by the existing preparation process, the pharmaceutical activity is low, and the effect of improving the reduction of SIRT1 protein caused by aging is not obvious.
The above-described preferred embodiments should be considered as examples of the embodiments of the present application, and any technical deductions, substitutions, improvements and the like, which are similar, approximate or based on the present application, should be considered as the protection scope of the present patent.
Claims (6)
1. The health care product oral liquid for delaying senility is characterized in that the content of polypeptide is 700-1900mg/100mL, the content of polysaccharide is 200-2000mg/100mL, the content of hydroxysafflor yellow A is 6-10mg/100mL, and the content of amygdalin is 24-40mg/100mL based on the total volume of the health care product oral liquid for delaying senility;
the polypeptide comprises sheep placenta polypeptide, fructus Lycii polypeptide, and arillus longan polypeptide;
the polysaccharide includes sheep placenta polysaccharide, fructus Lycii polysaccharide, and longan polysaccharide.
2. The preparation method of the health-care product oral liquid for delaying senility is characterized by comprising the following steps:
s1, extracting flos Carthami and semen Persicae;
pulverizing Carthami flos and semen Persicae, adding solvent, ultrasonic extracting, and filtering the extractive solution; concentrating the filtrate to obtain concentrated solution of Carthami flos and semen Persicae; volatilizing the solvent of the filter residue to obtain safflower and peach kernel dregs;
s2, hydrolyzing the raw materials in stages;
s2.1, adding water into the sheep placenta freeze-dried powder, heating and dispersing to obtain a sheep placenta freeze-dried powder aqueous solution, cooling the sheep placenta freeze-dried powder aqueous solution, adding a complex enzyme for hydrolysis, and performing hydrolysis reaction for 1-2 hours to obtain stage 1 hydrolysate;
s2.2, adding the wolfberry fruits, the arillus longan and the safflower and peach kernel dregs prepared in the step S1 into the stage 1 hydrolysate, adding papain, continuing hydrolysis, and carrying out hydrolysis reaction for 1-2 hours to obtain stage 2 hydrolysate;
s2.3, heating the hydrolysate in the stage 2 to inactivate the complex enzyme, and centrifuging to remove impurities to obtain a hydrolysis mixed solution;
s3, blending oral liquid;
and (4) uniformly mixing the safflower and peach kernel concentrated solution prepared in the step (S1) with the hydrolysis mixed solution prepared in the step (S2.3), and adjusting the water content in the solution to the required concentration to obtain the health-care oral liquid for delaying senility.
3. The method for preparing health care oral liquid for delaying senility according to claim 2,
the dosage ratio of the sheep placenta lyophilized powder to the safflower to the peach kernel to the medlar to the longan pulp is 1: (0.8-2.5): (1.8-6): (1.9-5.5): (1.9-5).
According to the mass percentage, the water content of the health care product oral liquid for delaying senility prepared in the step S3 is 80-95%.
4. The method for preparing health oral liquid for delaying aging according to claim 3,
in the step S2.1, the using amount of the complex enzyme is 1 to 3 percent of the weight of the sheep placenta freeze-dried powder;
the compound enzyme is compounded by papain and alkaline protease, wherein the papain: the ratio of alkaline protease used was 1: 1 to 3: 1;
in the step S2.2, the dosage of the papain is 1.8 to 3.5 percent of the weight of the medlar.
5. The method for preparing health oral liquid for delaying aging according to claim 4,
s2.1, controlling the cooling temperature of the sheep placenta freeze-dried powder aqueous solution at 35-45 ℃;
the hydrolysis reaction of step S2.1 is carried out at a pH of 8-9;
the hydrolysis reaction conditions of step S2.2 are carried out at a pH of 5-7.
6. The method for preparing health oral liquid for delaying aging according to any one of claims 2 to 5,
the health-care product oral liquid for delaying senescence comprises 700-1900mg/100mL of polypeptide, 200-2000mg/100mL of polysaccharide, 6-10mg/100mL of hydroxyl safflower yellow A and 24-40mg/100mL of amygdalin, based on the total volume of the oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597666.4A CN114766619A (en) | 2022-05-30 | 2022-05-30 | Health-care product oral liquid for delaying senility and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597666.4A CN114766619A (en) | 2022-05-30 | 2022-05-30 | Health-care product oral liquid for delaying senility and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114766619A true CN114766619A (en) | 2022-07-22 |
Family
ID=82409584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210597666.4A Pending CN114766619A (en) | 2022-05-30 | 2022-05-30 | Health-care product oral liquid for delaying senility and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114766619A (en) |
Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124627A (en) * | 1993-11-15 | 1996-06-19 | 王富宝 | Oral liquid for enhancing immunologic function |
| CN1159942A (en) * | 1997-01-20 | 1997-09-24 | 刘振瑞 | Placenta tonic and its processing and use |
| CN1376480A (en) * | 2001-03-28 | 2002-10-30 | 新疆生命红红花开发有限责任公司 | Oral liquid |
| CN1425452A (en) * | 2003-01-16 | 2003-06-25 | 上海寿祺多糖食品研究所 | Longan aril and wolfberry fruit polysaccharide health-care liquid and its preparing method and use |
| CN1432388A (en) * | 2002-12-26 | 2003-07-30 | 包铁男 | Sheep fetus peptide oral liquid and its prepn |
| CN1537465A (en) * | 2003-10-14 | 2004-10-20 | 大连轻工学院 | Functional food contg. ewe placenta, and its prepn. method |
| CN1613477A (en) * | 2003-11-06 | 2005-05-11 | 上海市中药研究所 | Medicine composition with spot dispelling function and preparation thereof |
| CN101953944A (en) * | 2009-07-14 | 2011-01-26 | 博辉生物药业(深圳)有限公司 | Compound preparation for deferring senility and preparation method thereof |
| CN102552537A (en) * | 2011-12-19 | 2012-07-11 | 东乌珠穆沁旗悦艺生物科技有限责任公司 | Chinese medicinal composition for treating qi and blood loss |
| CN102641397A (en) * | 2012-03-30 | 2012-08-22 | 常熟市海虞茶叶有限公司 | Sheep placenta-containing composite capsule and preparation method thereof |
| CN104126744A (en) * | 2014-07-01 | 2014-11-05 | 苟春虎 | Lycium ruthenicum Murr anti-agingbeauty tablet |
| CN104770738A (en) * | 2015-04-15 | 2015-07-15 | 威海御膳坊生物科技有限公司 | Sheep placenta freeze-dried powder compound preparation |
| CN105394680A (en) * | 2015-12-07 | 2016-03-16 | 广东生和堂健康食品股份有限公司 | Guiling jelly having skin improving effect and preparation method thereof |
| CN106727709A (en) * | 2016-11-24 | 2017-05-31 | 湖州珍露生物制品有限公司 | A kind of production technology of sheep placenta extract solution |
| CN107997186A (en) * | 2018-01-31 | 2018-05-08 | 天津天肽生物科技有限公司 | A kind of preparation method of matrimony vine polypeptide |
| CN108276502A (en) * | 2018-01-22 | 2018-07-13 | 邱媛媛 | A kind of extracting process of polysaccharides |
| CN110478305A (en) * | 2019-08-21 | 2019-11-22 | 银川凤仪堂生物工程有限公司 | A kind of preparation process and its application of sheep placenta extract |
| CN110746515A (en) * | 2019-10-28 | 2020-02-04 | 百瑞源枸杞股份有限公司 | Lycium barbarum polysaccharide, lycium barbarum red element and lycium barbarum polypeptide prepared by synchronous separation and preparation method thereof |
-
2022
- 2022-05-30 CN CN202210597666.4A patent/CN114766619A/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124627A (en) * | 1993-11-15 | 1996-06-19 | 王富宝 | Oral liquid for enhancing immunologic function |
| CN1159942A (en) * | 1997-01-20 | 1997-09-24 | 刘振瑞 | Placenta tonic and its processing and use |
| CN1376480A (en) * | 2001-03-28 | 2002-10-30 | 新疆生命红红花开发有限责任公司 | Oral liquid |
| CN1432388A (en) * | 2002-12-26 | 2003-07-30 | 包铁男 | Sheep fetus peptide oral liquid and its prepn |
| CN1425452A (en) * | 2003-01-16 | 2003-06-25 | 上海寿祺多糖食品研究所 | Longan aril and wolfberry fruit polysaccharide health-care liquid and its preparing method and use |
| CN1537465A (en) * | 2003-10-14 | 2004-10-20 | 大连轻工学院 | Functional food contg. ewe placenta, and its prepn. method |
| CN1613477A (en) * | 2003-11-06 | 2005-05-11 | 上海市中药研究所 | Medicine composition with spot dispelling function and preparation thereof |
| CN101953944A (en) * | 2009-07-14 | 2011-01-26 | 博辉生物药业(深圳)有限公司 | Compound preparation for deferring senility and preparation method thereof |
| CN102552537A (en) * | 2011-12-19 | 2012-07-11 | 东乌珠穆沁旗悦艺生物科技有限责任公司 | Chinese medicinal composition for treating qi and blood loss |
| CN102641397A (en) * | 2012-03-30 | 2012-08-22 | 常熟市海虞茶叶有限公司 | Sheep placenta-containing composite capsule and preparation method thereof |
| CN104126744A (en) * | 2014-07-01 | 2014-11-05 | 苟春虎 | Lycium ruthenicum Murr anti-agingbeauty tablet |
| CN104770738A (en) * | 2015-04-15 | 2015-07-15 | 威海御膳坊生物科技有限公司 | Sheep placenta freeze-dried powder compound preparation |
| CN105394680A (en) * | 2015-12-07 | 2016-03-16 | 广东生和堂健康食品股份有限公司 | Guiling jelly having skin improving effect and preparation method thereof |
| CN106727709A (en) * | 2016-11-24 | 2017-05-31 | 湖州珍露生物制品有限公司 | A kind of production technology of sheep placenta extract solution |
| CN108276502A (en) * | 2018-01-22 | 2018-07-13 | 邱媛媛 | A kind of extracting process of polysaccharides |
| CN107997186A (en) * | 2018-01-31 | 2018-05-08 | 天津天肽生物科技有限公司 | A kind of preparation method of matrimony vine polypeptide |
| CN110478305A (en) * | 2019-08-21 | 2019-11-22 | 银川凤仪堂生物工程有限公司 | A kind of preparation process and its application of sheep placenta extract |
| CN110746515A (en) * | 2019-10-28 | 2020-02-04 | 百瑞源枸杞股份有限公司 | Lycium barbarum polysaccharide, lycium barbarum red element and lycium barbarum polypeptide prepared by synchronous separation and preparation method thereof |
Non-Patent Citations (10)
| Title |
|---|
| 刘莉: "红花的研究概述", 《广州化工》 * |
| 刘辉: "羊胎盘多肽的制备工艺及抗氧化活性研究", 《中国优秀硕士学位论文全文数据库（电子期刊）》 * |
| 张淑二等: "胎盘的有效成分及其应用", 《动物医学进展》 * |
| 曹秀琴等: "枸杞胎盘液对小鼠免疫功能和应激反应的影响", 《宁夏医学杂志》 * |
| 李松林: "枸杞多肽的制备及其抗氧化活性研究", 《轻工学报》 * |
| 王兵等: "复方羊胚胎素对衰老模型大鼠血清中氧自由基水平的影响", 《中医学报》 * |
| 王晓娜等: "羟基红花黄色素A对过氧化氢致L02细胞谷胱甘肽氧化的影响", 《食品科学》 * |
| 王艺儒: "桃仁－红花药对对动静力失衡性大鼠椎间盘软骨终板细胞老化及凋亡的影响", 《环球中医药》 * |
| 田文静: "羟基红花黄色素A对6-OHDA诱导的帕金森病小鼠模型的神经保护作用及机制研究", 《卒中与神经疾病》 * |
| 高建德: "枸杞多糖改良差示酚硫法测定及其木瓜蛋白酶辅助提取工艺研究", 《西部中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412721B (en) | A kind of hypoglycemic bitter gourd polypeptide compound capsule and preparation method thereof | |
| CN113332354B (en) | Anti-saccharification anti-aging fermented composition and preparation method thereof | |
| CN104987431B (en) | A kind of mulberry active polysaccharide and its extraction method | |
| CN113841894B (en) | Preparation method of lycium ruthenicum anthocyanin extract and freeze-dried powder and application of lycium ruthenicum anthocyanin extract and freeze-dried powder in antioxidant and anti-aging products | |
| CN101780107A (en) | Hippocampus extract and preparation method thereof | |
| CN112159451A (en) | Gynostemma pentaphylla saponin extract and preparation method thereof | |
| CN112641826B (en) | Perilla seed extract and preparation method and application thereof | |
| CN115336688A (en) | A kind of method for preparing Sophora japonica beverage by hydrothermal treatment | |
| CN109400750A (en) | A kind of preparation method of avenabeta glucosan | |
| CN104982597A (en) | Multi-functional composite instant tea, as well as preparation method and use thereof | |
| Xing et al. | Optimization of steaming process for polysaccharides from Panax notoginseng by box-behnken response surface methodology and comparison of immunomodulatory effects of raw and steamed Panax notoginseng polysaccharides | |
| CN114766619A (en) | Health-care product oral liquid for delaying senility and preparation method thereof | |
| CN112625070A (en) | Ginsenoside wall-breaking purification technology | |
| CN115925761B (en) | Extraction method and application of Polygonatum sibiricum oligosaccharide | |
| CN110179845A (en) | A kind of Yellow Fructus Gardeniae electuary and preparation method thereof | |
| CN102690359B (en) | A kind of method extracting starch and cucurbitacin from Fructus Momordicae tuber | |
| CN109589400A (en) | A kind of composition with neuroprotective efficacy | |
| CN116725184A (en) | A method for preparing matsutake extract using cellulase combined with ultrasound | |
| CN110150521A (en) | An antioxidant health drink for nourishing the kidney and protecting the liver | |
| CN115844968A (en) | Houttuynia cordata extract and preparation method and application thereof | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN104353057B (en) | Blood-pressure reducing health care product containing european bird cherry anthocyanogen | |
| KR20220160869A (en) | Method for preparing leaf tea of Gynostemma pentaphyllum and method for preparing Gynostemma pentaphyllum extracts using the leaf tea prepared thereby | |
| CN105410281A (en) | Preparation method of composite tea composed of extracts of cyclocarya paliurus and gingko | |
| CN115245548A (en) | A kind of green money Poria medicinal composition with hypoglycemic effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220722 |